Stifel Financial
SPRY icon

Stifel Financial’s ARS Pharmaceuticals SPRY Stock Holding History

Stifel Financial’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-13,392
Closed -$234K – 3640
2025
Q2 		$234K Buy
13,392
+21
+0.2% +$303 ﹤0.01% 3185
2025
Q1 		$168K Sell
13,371
-388
-3% -$4.67K ﹤0.01% 3218
2024
Q4 		$145K Buy
13,759
+13
+0.1% +$182 ﹤0.01% 3212
2024
Q3 		$199K Buy
+13,746
New +$163K ﹤0.01% 3147
2023
Q3 		– Sell
-12,327
Closed -$82.6K – 3398
2023
Q2 		$82.6K Buy
+12,327
New +$82.3K ﹤0.01% 3194

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Stifel Financial's SPRY Position: Q3 2025 in Review

Stifel Financial sold out of ARS Pharmaceuticals (SPRY) in Q3 2025, closing a stake of 13,392 shares — an estimated $234K sold.

Stifel Financial first reported a position in SPRY in Q2 2023 and held it in 5 quarters. The position peaked at $234K in Q2 2025. 188 funds tracked by Wall St. Rank hold SPRY as of Q3 2025.

  • Stifel Financial reported no remaining ARS Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Stifel Financial sold 13,392 ARS Pharmaceuticals shares in Q3 2025, an estimated $234K.
  • Stifel Financial first reported a position in ARS Pharmaceuticals in Q2 2023 and held it in 5 quarters.
  • Stifel Financial's ARS Pharmaceuticals position peaked at $234K in Q2 2025.
  • 188 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2025.

Based on Stifel Financial's 13F filing for Q3 2025, filed 12 Nov 2025.